secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001558370-22-017028
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics reports Q3 2022 financials; FDA clears interim analysis for uproleselan Phase 3
--------------------------------------------------------------------------------

- Cash $51.6M as of Sep 30, 2022 vs $90.3M at Dec 31, 2021; cash runway extended to end of 2023.
- FDA cleared protocol amendment for interim utility analysis of uproleselan Phase 3 in relapsed/refractory AML.
- Blinded pooled survival data show patients living longer than historically expected; DMC meeting by end Q1 2023.
- Final survival events trigger projected around year-end 2023, later than originally anticipated.
- R&D expenses decreased to $4.9M from $13.3M YoY due to Phase 3 enrollment completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837022017028/0001558370-22-017028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837022017028/glyc-20221109x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-017028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer